Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

High-rolling investors have positioned themselves bullish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today ...

CASGEVY, a groundbreaking gene-edited therapy developed in collaboration with CRISPR Therapeutics (NASDAQ: CRSP), has received approval for SCD and TDT, marking a significant advancement in gene ...

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR Therapeutics (NASDAQ: CRSP) reached a major milestone in recent years. The company won its first regulatory approval for a product based on its gene-editing technology. In fact, this ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Below is Validea's guru fundamental report for CRISPR THERAPEUTICS AG (CRSP). Of the 22 guru strategies we follow, CRSP rates highest using our Value Investor model based on the published strategy ...

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $39.85 per share. By ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session ... Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, lost 1.89%. Shares of the company have depreciated by 14. ...